阿司匹林壳聚糖缓释片兔体内药物动力学研究  

Pharmacokinetics of aspirin sustained-release tablets containing chitosan in rabbits

作　　者：杨红梅[1] 陈旭[1] 赵坤杰[1] 

机构地区：[1]桂林医学院药学院药剂教研室,广西桂林541004

出　　处：《西北药学杂志》2004年第5期214-215,共2页Northwest Pharmaceutical Journal

摘　　要：目的　研究阿司匹林壳聚糖缓释片的体内药物动力学。方法　采用随机分组自身对照实验 ,分别给予家兔口服阿司匹林壳聚糖缓释片和阿司匹林肠溶片 ,定时收集血样 ,以分光光度法测定血药浓度 ,用 3P97药动学程序进行处理。结果　缓释片和肠溶片的 Tmax分别为 (6 .90± 0 .5 2 ) h和 (4.6 6± 0 .4 0 ) h;Cmax分别为 (5 .33±0 .38)和 (9.39± 0 .5 3) mg· L-1;AUC0→ 2 4h分别为 (6 3.4 5± 1.19)和 (6 4.85± 1.96 ) mg·h· L-1;相对生物利用度为 (97.92± 0 .0 3) %。结论　阿司匹林壳聚糖缓释片在家兔体内有缓释特征 ,可望为预防和治疗血栓形成提供一个新的剂型。Objective To study the pharmacokinetics of aspirin sustained-release tablets containing chitosan. Methods Aspirin sustained-release tablets containing chitosan or aspirin enteric-coated tablets were given to rabbits orally in randomized self-control cross-over design. The concentration of aspirin in serum was measured by ultraviolet spectrophotometry. The data was processed with the software 3P97. Results The parameters of the two formulations for aspirin: T max of sustained-release tablets and enteric-coated tablets were(6.90±0.52) and (4.66±0.40)h; C max were (5.33±0.38) and (9.39±0.53)mg·L -1; and AUC 0→24h were(63.45±1.19) and (64.85±1.96)mg·h·L -1, respectively. The relative bioavailability of aspirin sustained-release tablets containing chitosan was(97.92±0.03)%. Conclusions Aspirin sustained-release tablets containing chitosan showed a sustained-release effect in rabbits and could be used for the prevention and treatment of thrombogenesis.

关 键 词：阿司匹林 壳聚糖 缓释片 药物动力学 

分 类 号：R969.1[医药卫生—药理学]